Tofersen (Qalsody) for ALS
Also known as: Qalsody, BIIB067
The first gene therapy targeting a specific ALS-causing mutation, tofersen represents a paradigm shift toward precision medicine in ALS.
Mechanism of Action
Tofersen is an antisense oligonucleotide (ASO) that binds SOD1 mRNA via complementary base pairing, triggering RNase H-mediated mRNA degradation. This reduces production of toxic mutant SOD1 protein, the gain-of-function driver of SOD1-ALS. Administered intrathecally to bypass the blood-brain barrier.
General mechanism: Antisense oligonucleotide targeting SOD1 mRNA. RNase H-mediated gene silencing. Intrathecal delivery.
Current Evidence
The VALOR trial demonstrated changes in CSF SOD1 protein and neurofilament light chain (NfL) outcome measures. FDA accelerated approval (2023) for SOD1-ALS based on biomarker evidence. ATLAS trial studies presymptomatic SOD1 carriers. Real-world data has reported clinical outcomes in many patients.
Clinical Status: FDA accelerated approval (2023). ATLAS presymptomatic trial ongoing. Sets precedent for gene-targeted ALS therapies.
Safety Profile
Myelitis, radiculopathy, and aseptic meningitis reported. Intrathecal injection-related adverse events. Papilledema monitoring required. Generally manageable with monitoring.
Key Research Questions
- What is the long-term safety and efficacy of intrathecal ASO delivery?
- Can presymptomatic treatment prevent disease onset entirely in SOD1 carriers?
- Will this ASO approach extend to other genetic ALS subtypes (C9orf72, FUS)?
Frequently Asked Questions
Is tofersen effective for all types of ALS?
No. Tofersen (Qalsody) specifically targets SOD1 mutations, which account for about 2% of all ALS cases (20% of familial ALS). It works by degrading SOD1 mRNA via antisense oligonucleotide technology. Other ALS subtypes (C9orf72, TDP-43, sporadic) require different therapeutic approaches.
Tofersen side effects and monitoring
Common side effects include injection site reactions, joint pain, and fatigue. Serious risks include myelitis (spinal cord inflammation) and papilledema. Regular CSF sampling monitors neurofilament light chain levels as a biomarker of neurodegeneration response.